As with any medicine, the MHRA will keep the safety and effectiveness of mirdametinib under close review.
Similar Posts
The new Innovative Licensing and Access Pathway welcomes first investigational products
Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
New MHRA-supported research reveals patterns of vaccine-derived poliovirus spread and implications for global eradication efforts
Study provides crucial insights for targeting rapid response strategies and improving polio surveillance worldwide
How medicines affect gut bacteria could inform safer, more effective use
Understanding gut microbiome interactions with medicines could help explain differences in how people respond to treatment and build on existing medicine safety knowledge to support safer, more effective prescribing in the future.
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.
Guidance: Herbal medicines granted a traditional herbal registration (THR)
A list of herbal medicines currently holding a traditional herbal registration (THR) granted by the Medicines and Healthcare products Regulatory Agency (MHRA).